• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    JMP Securities initiated coverage on Zevra Therapeutics with a new price target

    9/24/24 8:29:54 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    JMP Securities initiated coverage of Zevra Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00
    Get the next $ZVRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watton Corey Michael bought $2,352 worth of shares (300 units at $7.84), increasing direct ownership by 20% to 1,800 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/31/25 8:05:01 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bode John B bought $79,624 worth of shares (10,000 units at $7.96), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      3/21/25 4:06:49 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Watton Corey Michael bought $3,958 worth of shares (500 units at $7.92), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      10/16/24 4:46:26 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

      Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the

      5/29/25 4:35:32 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

      ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote "FOR" Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the WHITE Proxy Card and "WITHHOLD" for Mangless Nominees CELEBRATION, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, today announced that all three leading proxy advisory firms, Institutional Shareholder Services ("ISS"), Glass Lewis & Co. ("Glass Lewis"), and Egan-Jones Proxy Services ("Egan

      5/21/25 7:30:00 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Reports First Quarter 2025 Financial Results and Corporate Update

      Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company's commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended Mar. 31, 2025. "We are continuing Zevra's transformation into a patient-centric, commercial-

      5/13/25 4:05:00 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

      1/8/25 8:49:26 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Zevra Therapeutics with a new price target

      Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

      10/7/24 8:28:23 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Zevra Therapeutics with a new price target

      JMP Securities initiated coverage of Zevra Therapeutics with a rating of Mkt Outperform and set a new price target of $17.00

      9/24/24 8:29:54 AM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal & Compliance Thompson Rahsaan sold $221,004 worth of shares (24,000 units at $9.21), decreasing direct ownership by 36% to 42,666 units (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      6/30/25 5:02:34 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal & Compliance Thompson Rahsaan converted options into 66,666 shares (SEC Form 4)

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      6/24/25 5:28:38 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shih Alvin

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      5/30/25 9:41:56 PM ET
      $ZVRA
      Biotechnology: Pharmaceutical Preparations
      Health Care